Sanofi has highlighted the progress being made on its research and development strategy during an analyst meeting in Paris.
In accordance with the company's 'Sustaining Innovation' business strategy, Sanofi has been able to cultivate a pipeline of 71 research projects, including 37 new molecular entities and novel vaccines.
“Sanofi has provided an update on its research strategy that demonstrates the significant progress being made on the development of several new compounds.“
At least ten pivotal phase III studies are expected to start over the next 12 months, which will evaluate new treatments for chronic obstructive pulmonary disease, eosinophilic oesophagitis, autosomal dominant polycystic kidney disease, type 2 diabetes, obesity,
primary progressive multiple sclerosis and non-small-cell lung cancer.
Regulatory filings expected in the next year include the investigational cancer drugs cemiplimab and isatuximab, as well as the novel type 1 diabetes therapy sotagliflozin and dupilumab, a potential treatment for uncontrolled, persistent asthma.
Dr Olivier Brandicourt, chief executive officer of Sanofi, said: "We have seen significant advancement on our ambition to sustain innovation in research and development, with the development of leading technology platforms and proof of concept demonstrated in multiple high-potential projects in late-stage trials."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical